These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. Mancino AT; Klimberg VS; Yamamoto M; Manolagas SC; Abe E J Surg Res; 2001 Sep; 100(1):18-24. PubMed ID: 11516200 [TBL] [Abstract][Full Text] [Related]
3. RANK ligand is a prerequisite for cancer-associated osteolytic lesions. Kitazawa S; Kitazawa R J Pathol; 2002 Oct; 198(2):228-36. PubMed ID: 12237883 [TBL] [Abstract][Full Text] [Related]
4. Receptor activator of NF-kappaB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147. Rucci N; Millimaggi D; Mari M; Del Fattore A; Bologna M; Teti A; Angelucci A; Dolo V Cancer Res; 2010 Aug; 70(15):6150-60. PubMed ID: 20631064 [TBL] [Abstract][Full Text] [Related]
5. Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Bendre MS; Gaddy-Kurten D; Mon-Foote T; Akel NS; Skinner RA; Nicholas RW; Suva LJ Cancer Res; 2002 Oct; 62(19):5571-9. PubMed ID: 12359770 [TBL] [Abstract][Full Text] [Related]
6. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635 [TBL] [Abstract][Full Text] [Related]
7. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334 [TBL] [Abstract][Full Text] [Related]
8. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Lu Y; Cai Z; Xiao G; Keller ET; Mizokami A; Yao Z; Roodman GD; Zhang J Cancer Res; 2007 Apr; 67(8):3646-53. PubMed ID: 17440076 [TBL] [Abstract][Full Text] [Related]
9. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315 [TBL] [Abstract][Full Text] [Related]
10. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Fisher JL; Thomas-Mudge RJ; Elliott J; Hards DK; Sims NA; Slavin J; Martin TJ; Gillespie MT Cancer Res; 2006 Apr; 66(7):3620-8. PubMed ID: 16585187 [TBL] [Abstract][Full Text] [Related]
11. [Angiogenic effect of interleukin-8 in breast cancer and its association with estrogen receptor]. Lin Y; Wang SM; Huang RP Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(20):1419-23. PubMed ID: 16029657 [TBL] [Abstract][Full Text] [Related]
12. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production. Lee SK; Gardner AE; Kalinowski JF; Jastrzebski SL; Lorenzo JA Bone; 2006 May; 38(5):678-85. PubMed ID: 16309985 [TBL] [Abstract][Full Text] [Related]
13. Nuclear factor-kappaB-dependent mechanisms in breast cancer cells regulate tumor burden and osteolysis in bone. Gordon AH; O'Keefe RJ; Schwarz EM; Rosier RN; Puzas JE Cancer Res; 2005 Apr; 65(8):3209-17. PubMed ID: 15833852 [TBL] [Abstract][Full Text] [Related]
15. Malignant B-lymphoid cells with bone lesions express receptor activator of nuclear factor-kappaB ligand and vascular endothelial growth factor to enhance osteoclastogenesis. Shibata H; Abe M; Hiura K; Wilde J; Moriyama K; Sano T; Kitazoe K; Hashimoto T; Ozaki S; Wakatsuki S; Kido S; Inoue D; Matsumoto T Clin Cancer Res; 2005 Sep; 11(17):6109-15. PubMed ID: 16144909 [TBL] [Abstract][Full Text] [Related]
16. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. Lau YS; Sabokbar A; Gibbons CL; Giele H; Athanasou N Hum Pathol; 2005 Sep; 36(9):945-54. PubMed ID: 16153456 [TBL] [Abstract][Full Text] [Related]
17. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells. Fujisaki K; Tanabe N; Suzuki N; Kawato T; Takeichi O; Tsuzukibashi O; Makimura M; Ito K; Maeno M Life Sci; 2007 Mar; 80(14):1311-8. PubMed ID: 17306833 [TBL] [Abstract][Full Text] [Related]
18. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477 [TBL] [Abstract][Full Text] [Related]
19. Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity. Pederson L; Winding B; Foged NT; Spelsberg TC; Oursler MJ Cancer Res; 1999 Nov; 59(22):5849-55. PubMed ID: 10582709 [TBL] [Abstract][Full Text] [Related]
20. Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer. Singh B; Berry JA; Vincent LE; Lucci A J Surg Res; 2006 Jul; 134(1):44-51. PubMed ID: 16678856 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]